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Abstract
Background: The ECOG-ACRIN Cancer Research Group evaluated rituximab treatment schedules for patients with
newly-diagnosed low-tumor-burden follicular-lymphoma (FL). All patients received 4-weekly rituximab treatments as
induction therapy. Clinically-responding patients were randomized to receive rituximab every 13 weeks
(“maintenance”) vs. no additional rituximab until progression (“non-maintenance”). Based on “time-to-rituximabfailure (TTRF)”, the study-committee reported there was no overall-benefit for maintenance rituximab in this setting.
Tumor-reactive mAbs, like rituximab, trigger natural killer (NK) cells. NK-cell responses are regulated, in part, by
interactions between killer immunoglobulin-like receptors (KIRs) on NK cells and their interactions with KIR-ligands.
In a separate study of children with neuroblastoma treated with a different mAb, we found certain KIR/KIR-ligand
genotypes associated with improved outcome. Here, we assessed whether a subset of FL patients show improved
outcome from the maintenance rituximab based on these same KIR/KIR-ligand genotypes.
Methods: Genotypes for KIR/KIR-ligand were determined and assessed for associations with outcome [duration of
response, TTRF and % tumor shrinkage] as a post-hoc analysis of this phase III trial. Our primary objective was to
assess specific KIR/KIR-ligand genotype associations, followed by separate prespecified KIR/KIR-ligand genotype
associations in follow-up analyses. Statistical analyses for association of genotype with clinical outcome included:
Log-rank tests and Cox proportional hazards regression models to assess duration of response and TTRF; analysis of
variance (ANOVA) was used for assessment of % tumor shrinkage.
Results: We found that patients inheriting KIR2DL2 and its ligand (HLA-C1) along with KIR3DL1 and its ligand (HLABw4) had improved outcome over patients without this genotype. In addition, patients with KIR2DL2 and HLA-C1
along with KIR3DL1 and HLA-Bw4 also showed improved duration of response and tumor shrinkage if they
received maintenance, while patients without this genotype showed no such improvement when receiving
maintenance.
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Conclusions: The data presented here indicate that a subset of FL patients, identified by certain KIRs/KIR-ligands,
have improved outcome and may benefit from additional rituximab treatment. Taken together, this suggests that
the efficacy of tumor-reactive mAb treatment for some patients is influenced by KIRs on NK cells. However, prior to
considering these genotypes in a clinically-actionable manner, these findings need independent validation in other
studies.
Keywords: KIR, HLA, Follicular lymphoma, NK cells, Rituximab, Immunotherapy, Monoclonal antibody, ADCC, CD20,
MHC class I

Background
The most common form of indolent lymphoma is follicular lymphomas (FL). The use of rituximab to treat FL
has markedly transformed the care of these patients [1,
2]. For patients with low-tumor burden FL, a maintenance rituximab strategy has been shown to improve the
progression-free survival following induction with either
chemotherapy or rituximab [3–5]. Yet, whether other
clinical outcome parameters could benefit from the continual rituximab treatment schedule (maintenance rituximab vs. a close “watch and wait” approach) was unclear
[6]. Additionally, concerns related to the added healthcare expenditures required for a maintenance treatment
schedule suggested that it may be more cost-efficient to
treat with rituximab on a less frequent basis [6–8]. As
such, the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) conducted and reported results from a phase
III clinical trial (E4402) to determine the optimal rituximab dosing strategy for patients with low-tumor burden
FL [6]. In this report of the E4402 trial, Kahl and colleagues concluded that maintenance rituximab treatment
(continual doses of rituximab every 13 weeks) provided
no benefit in the time to rituximab failure for this
population of low-tumor burden FL patients, compared
to a non-maintenance rituximab treatment schedule
(an additional course of 4 weekly doses of rituximab
only upon disease progression) [6]. The purpose of this
present study was to determine if inherited genotypic
variances in genes that influence immune function, and
potentially rituximab’s antitumor effects, may identify
subpopulations of patients that differ in their outcome
following maintenance vs. non-maintenance rituximab
schedules [8, 9].
In a separate study of FL patients, patients with lower
NK cell counts had inferior clinical prognosis [10]. This
result suggests that NK cell count may be used as a
prognostic biomarker for FL patients, and that treatments designed to activate NK cells might potentially be
beneficial [10]. NK cells contribute to the anti-tumor effects of rituximab via antibody-dependent cell-mediated
cytotoxicity (ADCC), and several studies have assessed
NK cell specific immunogenetic factors that may be predictive of response to rituximab treatment in FL patients

[11–15]. We hypothesize that NK cell specific immunogenetic factors influence the clinical outcome following
rituximab treatment for some FL patients, and that the
maintenance rituximab treatment schedule differentially
impacts clinical outcome dependent upon individual
genotypic differences.
NK cell activation is based on the balance of inhibitory
and activating signals transmitted by receptors on NK
cells. One class of these receptors is killer-cell
immunoglobulin-like receptors (KIRs); some of these
interact with certain class I HLA molecules (which can
function as KIR ligands) to modulate NK cell responses
[16, 17]. The interactions between endogenous KIRs and
KIR-ligands modulate NK cell function and immunotherapeutic responses [12, 18–21]. During NK cell maturation, NK cells lacking inhibitory KIRs specific for
self-HLA class I become less potent than NK cells expressing one or more inhibitory receptors for self-HLA
class I through a process termed licensing [22, 23]. Yet,
these same inhibitory KIRs can suppress mature NK
cells through specific interactions with the class I HLA
molecules that function as their ligands when expressed
by tumors and other nucleated cells.
Prior clinical studies have reported associations
between KIR/KIR-ligand genotypes and patient clinical
response in various immunotherapeutic settings that
likely involve NK cells [12, 18, 20, 24–29]. In a separate
randomized clinical trial of patients with neuroblastoma,
we have shown that patients with certain KIR/KIR-ligand
genotypes benefited from treatment with mAb-based
immunotherapy [dinutuximab (anti-GD2 mAb) + GMCSF + interleukin-2] while patients with the opposing
KIR/KIR-ligand genotype were not clinically influenced
by the immunotherapy treatment [30]. In addition, we
found that patients that did not receive immunotherapy responded differently dependent upon which KIR/
KIR-ligand genotypes they had, suggesting that NK
cells influence outcome even in the absence of immunotherapy [30].
In this study, we assessed whether the presence of
certain KIR/KIR-ligand genotypes might affect whether
the use of maintenance rituximab influences outcome.
Separately, we also investigated whether certain KIR/
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KIR-ligand genotypes influenced the clinical outcome
based on the rituximab treatment schedule (i.e. how
KIR/KIR-ligand genotype might affect clinical outcome
within the maintainance or non-maintenance treatment
schedules). The primary endpoint in the E4402 clinical
trial was the time to rituximab failure (TTRF). In this
present study, we evaluated associations of KIR/KIR-ligand genotype with TTRF, using determinants based on
biological causes (detailed in the statistical section of
Methods). We also assessed two additional biologically
relevant clinical parameters: duration of response and %
tumor shrinkage. In the current report, we found that
for subsets of patients with certain KIR/KIR-ligand genotypes (but not for others), clinical outcome (TTRF) was
improved by the maintenance rituximab treatment
schedule.

Methods
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web-based application designed to support data capture
for research studies, providing: 1) an intuitive interface for
validated data entry; 2) audit trails for tracking data
manipulation and export procedures; and 3) procedures
for importing data from external sources [33]. The clinical
outcome data from the ECOG-ACRIN study database
(which is HIPAA compliant) in Excel were merged with
the genotyping data in REDCap to create a SAS dataset
for analysis.
KIR/KIR-ligand interaction analysis

Individuals that have all KIR-ligands present for the
inhibitory KIRs they possess were defined as having a
“KIR-ligands present” genotype. Individuals that lack any
KIR-ligand for any one of the KIR genes they possess
were defined as having a “KIR-ligand missing” genotype
[18, 20, 29, 30]. Detailed descriptions of these genotypes
can be found in Additional file 1: Table S2.

Clinical trial and clinical samples

The phase III ECOG-ACRIN E4402 clinical trial (ClinicalTrials.gov #NCT00075946) evaluated the efficacy of single
agent, rituximab therapy for adults with low-tumor burden indolent lymphoma. Clinical results from this study
have been reported elsewhere [6]. A total of 408 patients
with follicular lymphoma were entered, 289 of which
responded and were randomized to maintenance vs
non-maintenance therapy with rituximab. Disease measurements were obtained every 13 weeks [6]. Of the 408
patients, 213 patients had evaluable DNA and clinical
data; of the 289 responding randomized patients, 159 had
evaluable DNA and clinical data for this study. Clinical
and demographic data for the 213 patients and the 159
randomized patients for which DNA and clinical data
were evaluable (non-maintenance n = 80 and maintenance
n = 79) are included in Additional file 1: Table S1, along
with comparative data for the 289 responding patients
reported on in the primary clinical report. The clinical
trial was conducted in accordance with the Helsinki
Declaration of 1975.
Genotyping

KIR gene status was determined by a real time PCR
technique [31, 32]. The genotypes of KIR-ligand
(HLA-C1, HLA-C2, HLA-Bw4) were performed in a
blinded fashion, and determined by PCR-SSP using the
KIR HLA Ligand SSP typing kit (Olerup) with GoTaq
DNA Polymerase (Promega). Additional genotyping details can be found in the supplemental methods section.
Data management

Study data (genotyping data from our lab) were entered
into and managed using the REDCap system hosted at the
University of Wisconsin-Madison. REDCap (Research
Electronic Data Capture) is a secure, HIPAA-compatible,

Statistical methods

The primary objective was to evaluate the association of
clinical outcome with treatment regimen and KIR-ligand
status (all KIR-ligands present compared with KIR-ligands missing). Other analyses were exploratory, but the
KIR/KIR-L genotype combinations evaluated here were
performed based on associations with outcome for similar KIR/KIR-L genotype combinations in a prior study of
neuroblastoma patients treated with a separate mAb
[30]. Thus, statistical analyses were performed, and p
values are reported, without any adjustment for multiplicity of testing. Only randomized patients were included
in the analyses. The post-hoc analysis of the clinical outcomes from this phase III trial that were assessed included the duration of response (n = 155), the time to
rituximab failure (TTRF) (n = 159), and % tumor shrinkage (n = 139). For each of the clinical parameters
assessed, Additional file 1: Table S3 includes the mean/
median response data with 95% confidence intervals.
The duration of response was defined as the time from
randomization (following an initial response to the
induction rituximab treatment) to documented first
disease progression. The TTRF was defined as the time
from randomization to treatment failure, as reported by
Kahl et al. [6]. Treatment failure was defined as whichever came first of: 1) the time at which patients no
longer responded to rituximab [disease progression for
patients receiving maintenance; no response to retreatment
rituximab or time to progression [< 26 weeks from day 1 of
last rituximab for patients in the non-maintenance treatment schedule], 2) the time at which an alternative therapy
was initiated, or 3) the time at which patients were determined unable to complete their assigned rituximab schedule [6]. For all TTRF analyses reported here, treatment
failures that were considered non-biological (largely the
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decision to change to alternate therapy by the patient or
physician) were censored, and as presented in the supplemental materials in the initial clinical report [6].
The % tumor shrinkage was defined as the % change
in tumor size from the baseline measurement at the time
of randomization (measured 13 weeks after initiating the
induction rituximab treatment) to the smallest tumor
size obtained post-randomization, only including those
who had a partial response 13 weeks after initiating the
induction rituximab (n = 139). While all evaluable randomized patients could be analyzed for duration of response, tumor shrinkage following randomization could
not be calculated for 16 patients (10 in non-maintenance
and 6 in maintenance) that had achieved a complete
response with a tumor measurement of zero at week 13 of
induction, as it was impossible to measure any further
shrinkage after their complete response measured at week
13. Changes in tumor size were represented using box
plots (described in detail in supplemental materials).
Log-rank tests and Cox proportional hazards regression models were used to compare the duration of response and TTRF by treatment and genotype
combinations. For the % tumor shrinkage, analysis of
variance (ANOVA) was used. For our analyses, the associations between outcome and KIR/KIR-ligand were
evaluated using Cox regression models with treatment
group and KIR/KIR-ligand genotype as the main effects.
In addition, we evaluated for possible interaction effects

between treatment schedule and KIR/KIR-ligand genotype on outcome. For the analyses assessing associations
of outcome with specific KIRs and their ligands (as in
Tables 1 and 2), we set a minimal p-value of p < 0.100
requirement in the interaction analysis in order to
subsequently perform association comparisons directly
between individual genotype groups and outcome.
Statistical analyses were performed using SAS v9.4 (SAS
Institute, Cary, NC).

Results
KIR ligand missing status does not significantly influence
TTRF, duration of response or tumor shrinkage

In some previous studies, patients with at least one
KIR-ligand missing (“KIR-ligand missing”) had improved
clinical outcome as compared to those with all KIRigands present (“KIR-ligands present”) when treated with
NK-based immunotherapy [18, 25, 26, 29]. The genotypes
used to define KIR-ligands present vs. KIR-ligand missing
are detailed in Additional file 1: Table S2. Based on the
findings from these prior studies, we hypothesized that FL
patients that received rituximab therapy that had the
KIR-ligand missing genotype would have improved outcome as compared to those patients with KIR-ligands
present. However, here we found no significant association
between TTRF with KIR-ligands present vs. KIR-ligand
missing status (Fig. 1a) amongst either those receiving
maintenance or those receiving non-maintenance.

Table 1 Interaction analyses for individual KIR and KIR ligand genotypes with TTRF
TTRF
Line

Treatment

Genotype Group

Number of Events/n

4 yr Fail Rate (95% CI)a %

Interaction p-value

1

Maintenance

KIR2DL1+/C2+

21/52

38 (25–54)

0.524

2

Maintenance

not KIR2DL1+/C2+

7/28

30 (15–56)

3

Non-Maintenance

KIR2DL1+/C2+

18/49

38 (26–55)

4

Non-Maintenance

not KIR2DL1+/C2+

6/30

21 (9–43)

5

Maintenance

KIR2DL2+/C1+

11/36

32 (18–53)

6

Maintenance

not KIR2DL2+/C1+

17/44

38 (25–56)

7

Non-Maintenance

KIR2DL2+/C1+

6/28

24 (10–49)

8

Non-Maintenance

not KIR2DL2+/C1+

18/51

36 (24–52)

9

Maintenance

KIR2DL3+/C2+

17/56

33 (21–50)

10

Maintenance

not KIR2DL3+/C2+

11/24

41 (23–64)

11

Non-Maintenance

KIR2DL3+/C2+

16/60

27 (17–43)

12

Non-Maintenance

not KIR2DL3+/C2+

8/19

45 (25–70)

13

Maintenance

KIR3DL1+/Bw4+

20/54

38 (25–55)

14

Maintenance

not KIR3DL1+/Bw4+

8/26

29 (15–52)

15

Non-Maintenance

KIR3DL1+/Bw4+

13/50

25 (15–41)

16

Non-Maintenance

not KIR3DL1+/Bw4+

11/29

43 (25–66)

95% Confidence interval; lines 13-14 (bolded text) had a p-value <0.100 and were analyzed further for associations with outcome

a

0.547

0.982

0.055
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Table 2 Interaction analyses for double-inhibitory KIR and KIR ligand genotypes with TTRF
TTRF
Line Treatment

Genotype Group

Number of Events/n 4 yr Fail Rate (95% CI)a % Interaction p-value

1

Maintenance

KIR2DL1+/C2+ and KIR3DL1+/Bw4+

17/44

37 (24–54)

2

Maintenance

not KIR2DL1+/C2+ and KIR3DL1+/Bw4+

11/36

34 (19–55)

3

Non-Maintenance

KIR2DL1+/C2+ and KIR3DL1+/Bw4+

10/32

33 (18–54)

4

Non-Maintenance

not KIR2DL1+/C2+ and KIR3DL1+/Bw4+

14/47

31 (19–48)

5

Maintenance

Group 1: KIR2DL2+/C1+ and KIR3DL1+/Bw4+

9/22

45 (24–72)

6

Maintenance

Group 2: not KIR2DL2+/C1+ and KIR3DL1+/Bw4+ 19/58

7

Non-Maintenance Group 1: KIR2DL2+/C1+ and KIR3DL1+/Bw4+

8

Non-Maintenance Group 2: not KIR2DL2+/C1+ and KIR3DL1+/Bw4+ 20/56

4/23

0.694

0.068

32 (21–47)
17 (6–44)
38 (26–54)

9

Maintenance

KIR2DL3+/C1+ and KIR3DL1+/Bw4+

12/35

38 (26–54)

10

Maintenance

not KIR2DL3+/C1+ and KIR3DL1+/Bw4+

16/45

34 (21–51)

11

Non-Maintenance

KIR2DL3+/C1+ and KIR3DL1+/Bw4+

10/37

25 (13–44)

12

Non-Maintenance

notT KIR2DL3+/C1+ and KIR3DL1+/Bw4+

14/42

38 (24–57)

0.447

95% Confidence interval; lines 5-8 (bolded text) had a p-value <0.100 and were analyzed further for associations with outcome

a

Similarly, KIR-ligands present vs. KIR-ligand missing
status did not influence duration of response (Fig. 1b) or
tumor shrinkage (Fig. 1c) for either treatment regimen. In
addition, the treatment regimen (maintenance vs.
non-maintenance) did not influence TTRF for patients
with either KIR-ligands present or KIR-ligand missing
(Fig. 1a), consistent with the data for the overall group of
patients from the initial clinical report [6]. In contrast,
amongst patients with KIR ligands present, those receiving
maintenance showed significantly increased duration of
response (Fig. 1b) and tumor shrinkage (Fig. 1c), and those
with KIR ligands missing that received maintenance also
showed increased duration of response (Fig. 1b).
Specific individual inhibitory KIR/KIR-ligand combinations:
The presence of KIR3DL1 and its HLA-Bw4 ligand, but not
absence of KIR3DL1 and HLA-Bw4, are associated with
improved outcome for patients receiving rituximab
maintenance treatment

We hypothesized that patients with all KIR-ligands
present have NK cells that are more inhibited due to the
presence of KIR-ligands for all of the inhibitory KIRs
inherited [18, 20]. Yet, there is also the concept that
those patients with KIR-ligands present have more licensed NK cells that may be able to better lyse
rituximab-treated tumor cells [22, 34, 35]. We further
assessed whether there was a differential influence on
outcome in this clinical trial dependent upon the presence or absence of specific inhibitory KIRs/KIR-ligands.
HLA-C alleles can be divided based on their KIR binding as HLA-C1 or HLA-C2 containing epitopes [19, 36].
As C1 and C2 are alleles, every individual will genotype
as either HLA-C1/C1, HLA-C1/C2, or HLA-C2/C2.

KIR2DL1 recognizes HLA-C2 as its ligand. Thus individuals with both KIR2DL1 and HLA-C2 (designated as
KIR2DL1+/C2+) include those that have KIR2DL1+ and
also have HLA-C2+ (HLA-C genotype of either C1/C2
or C2/C2). All other possible genotypes regarding KIR
2DL1 and HLA-C are designated as not KIR2DL1+/C2+
and include the following genotypes: (KIR2DL1+/C2-,
KIR2DL1−/C2+, or KIR2DL1−/C2-) described in detail
in Additional file 1: Table S4. KIRs 2DL2 and 2DL3 each
recognize HLA-C1 as their KIR-ligand. Thus KIR2DL2
+/C1+ individuals have KIR2DL2+ with HLA-C1+
(HLA-C genotype of either C1/C1 or C1/C2); all other
possible genotypes of KIR2DL2 and HLA-C are designated as not KIR2DL2+/C1+, as detailed in Additional
file 1: Table S4. Similarly, KIR2DL3+/C1+ individuals
have KIR2DL3+ with HLA-C1+ (HLA-C genotype of
C1/C1 or C1/C2); all other KIR2DL3 and HLA-C genotypes are designated as not KIR2DL3+/C1+ (Additional
file 1: Table S4). KIR3DL1 recognzies the HLA-Bw4
epitope on HLA-B and HLA-A. Thus KIR3DL1+/Bw4+
individuals include all those that have KIR3DL1+ with
either HLA-B-Bw4+ and/or HLA-A-Bw4+ [37]. All
other KIR3DL1 and HLA-Bw4 genotypes are designated
as not KIR3DL1+/Bw4+ (Additional file 1: Table S4).
To assess whether the effect of individual KIR/KIR-ligand pairs may be influenced by treatment regimen, we
first did an interaction analysis between outcome for
each treatment regimen and genotype status for individual KIR/KIR-ligand pairs (Table 1). Since TTRF was the
primary endpoint in the E4402 clinical trial [6], for the
initial interaction analysis, we used TTRF as our primary
endpoint. Only the genotypes determined by KIR3DL1/
Bw4 showed an interaction p-value ≤0.100 with
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Fig. 1 Associations of overall KIR/KIR-ligand status with clinical outcomes. Kaplan-Meier curves for TTRF (non-biological events censored) (a) and
for duration of response (b) compare those treated with maintenance rituximab and KIR-ligands present (Line 1: solid-black line), those treated
with maintenance rituximab and KIR-ligand missing (Line 2: dashed-black line), those treated with non-maintenance rituximab and KIR-ligands
present (Line 3: solid-red line) and those treated with non-maintenance rituximab and KIR-ligand missing (Line 4: dashed-red line). c displays boxplots for % tumor shrinkage for the four groups above (p-value not shown if p > 0.1; “*” indicates p < 0.05). Outlying values are shown as filled
circles outside the horizontal lines

treatment regimen (corresponding to lines 13–16 in
Table 1). This p-value of 0.055 justified further analyses
of associations of outcome (shown in Fig. 2) with these 4
individual KIR/KIR-ligand groups.
For patients that were KIR3DL1+/Bw4+, those that
received the maintenance regimen showed significantly
improved duration of response (p < 0.001, Fig. 2b) and %
tumor shrinkage (p = 0.04, Fig. 2c) vs. those that did not
receive maintenance. There was no significant improvement in duration of response or tumor shrinkage associated with maintenance treatment vs. non-maintenance
for the patients that were not KIR3DL1+/Bw4+. These
results suggest that the maintenance regimen improved clinical outcome for KIR3DL1+/Bw4+ patients.

Additionally, amongst patients receiving maintenance
rituximab, KIR3DL1+/Bw4+ patients had improved
outcome compared to those that were not KIR3DL1
+/Bw4+ (p < 0.05 for TTRF, Fig. 2a; p = 0.01 for duration of response, Fig. 2b; and a trend of p = 0.07 for
tumor shrinkage, Fig. 2c).
Inhibitory KIR2DL2/C1+ interactions in combination with
KIR3DL1/KIR-ligand interactions improve outcome for
patients receiving rituximab maintenance treatment

While the KIR-ligands present genotype (as shown in
Fig. 1) considers all three KIR-ligands (HLA-C1,
HLA-C2 and HLA-Bw4) equally contributing to the licensing or inhibition of NK cells, (described in
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Fig. 2 Associations of KIR3DL1 and its ligand status with clinical outcomes. Kaplan-Meier curves for TTRF (non-biological events censored) (a) and
for duration of response (b) compare those treated with maintenance rituximab and KIR3DL1+/Bw4+ (Line 1: solid-black line), those treated with
maintenance rituximab and not KIR3DL1+/Bw4+ (Line 2: dashed-black line), those treated with non-maintenance rituximab and KIR3DL1+/Bw4+
(Line 3: solid-red line) and those treated with non-maintenance rituximab and not KIR3DL1+/Bw4+ (Line 4: dashed-red line). c displays box-plots
for percent tumor shrinkage for the four groups above (p-value not shown if p > 0.1). Outlying values are shown as filled circles outside the
horizontal lines. (“*” indicates p < 0.05; “***” indicates p < 0.001)

Additional file 1: Table S2), we assessed whether certain
combinations of KIR2DL1, KIR2DL2 or KIR2DL3 and
their KIR-ligands together with KIR3DL1 and its
KIR-ligand would affect patients’ response to rituximab
differently. We and others have found that a subset of
patients, based on the presence of KIR2DL1, KIR2DL2
or KIR2DL3 and their respective ligands together with
the presence of KIR3DL1 and its ligand, benefited from
anti-GD2-based treatment while the converse genotype
did not [38, 39]. As mentioned above, HLA-C1 and
HLA-C2 are alleles, and thus everyone will have either
HLA-C1 and/or HLA-C2. With this in mind, since every
individual will have an interaction of inhibitory

KIR2DL1, KIR2DL2 or KIR2DL3 with their HLA-C ligands, we assessed the effects of the presence or absence
of KIR3DL1 and its ligand on outcome in combination
with the various possible combinations of KIR2DL1,
KIR2DL2 or KIR2DL3 with their ligands.
The following dual combinations of inhibitory KIRs
were compared:
KIR2DL1+/C2+/KIR3DL1+/Bw4+ vs. not KIR2DL1+
/C2+/KIR3DL1+/Bw4+; KIR2DL2+/C1+/KIR3DL1+/Bw
4+ vs. not KIR2DL2+/C1+/KIR3DL1+/Bw4+;and KIR
2DL3+/C1+/KIR3DL1+/Bw4+ vs. not KIR2DL3+/C1+
/KIR3DL1+/Bw4. These double-inhibitory KIR/KIR-li
gand genotype combinations are described in further
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Group 2 (p = 0.04 for TTRF, Fig. 3a; p = 0.006 for
duration of response, Fig. 3b; p = 0.08 for tumor shrinkage, Fig. 3c).

detail in Additional file 1: Table S5. For these “double”
combinations, the only interaction comparison that met
our predefined statistical cutoff of a p-value ≤0.100 was
the comparison of KIR2DL2+/C1+/KIR3DL1+/Bw4+ vs.
not KIR2DL2+/C1+/KIR3DL1+/Bw4+, herein referred to
as “Group 1” vs. “Group 2”, respectively (as shown in
Table 2, lines 5–9, p = 0.068).
Subgroup comparisons were done for Group 1 vs.
Group 2 treated with maintenance vs. non-maintenance
rituximab (Fig. 3). Group 1 patients treated with maintenance vs. non-maintenance showed a trend toward
improved TTRF (p = 0.10, Fig. 3a), improved duration of
response (p < 0.001, Fig. 3b), and a trend toward improved % tumor shrinkage (p = 0.08, Fig. 3c). Conversely,
those in Group 2 did not even have a trend toward improved clinical outcome for any of these 3 parameters if
treated with maintenance vs. non-maintenance rituximab (Fig. 3a, b and c). In addition, amongst patients that
were treated with maintenance rituximab, Group 1 had
improved clinical outcome as compared to those in

A

Discussion
In this study, we found no influence of the KIR-ligands
present vs. KIR-ligand missing genotypes on clinical outcome. However, we did find that for some FL patients,
treatment with maintenance rituximab improved their
clinical outcome based on their KIR/KIR-ligand genotype. Namely, the 28% (45 of 159) of this patient population with genotypes in Group 1 (Fig. 3a) appear to have
improved outcome (significant for duration of response
and tumor shrinkage and a trend for TTRF) from maintenance vs. non-maintenance rituximab. In contrast, for
those remaining 72% of patients with the Group 2 genotype, we found insufficient evidence of an improvement
in outcome if treated with maintenance compared to the
non-maintenance rituximab treatment schedule [18, 20].
We recently found a similar result for these same
B

C

Fig. 3 Associations of KIR2DL2 and KIR3DL1 and their ligand status with clinical outcomes. Kaplan-Meier curves for TTRF (non-biological events
censored) (a) and for duration of response (b) compare those treated with maintenance rituximab and Group 1 (KIR2DL2+/C1+/KIR3DL1+/Bw4+)
(Line 1: solid-black line), those treated with maintenance rituximab and Group 2 (not KIR2DL2+/C1+/KIR3DL1+/Bw4+) (Line 2: dashed-black line),
those treated with non-maintenance rituximab and Group 1 (Line 3: solid-red line) and those treated with non-maintenance rituximab and Group
2 (Line 4: dashed-red line). c displays box-plots for percent tumor shrinkage for the four groups above (p-value not shown if p > 0.1). Outlying
values are shown as filled circles outside the horizontal lines. (“*” indicates p < 0.05; “***” indicates p < 0.001)
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genotypes in a separate randomized study of
anti-GD2-based mAb immunotherapy for children with
high-risk neuroblastoma. Namely, neuroblastoma patients with the Group 1 genotype appear to have improved outcome from anti-GD2-based immunotherapy
(vs. no immunotherapy), while for those patients with
the Group 2 genotype, no improvement in outcome
from the anti-GD2-based immunotherapy (vs. no immunotherapy) was observed [38]. These similar results
regarding improved outcome with the immunotherapy
regimens for patients with the Group 1 genotype in
these two separate randomized studies, [which include
two different patient poluations (adult vs. pediatric
patients), two different disease types (FL vs. neuroblastoma), and two different anti-tumor-reactive mAb-based
immunotherapies (rituximab/anti-CD20 vs. dinutuximab/anti-GD2)], provides some degree of validation for
this finding. In addition to the Group 1 genotype, we recently reported similar findings for patients with certain
HLA-Bw4 isoforms from these same two clinical studies
[40]. In that report, we evaluated the role of three separate HLA-Bw4 isoforms (HLA-A-Bw4, HLA-B-Bw4-I80
and HLA-B-Bw4-T80). In both clinical trials, patients
with KIR3DL1+/A-Bw4+ or with KIR3DL1+/B-Bw4-T80
+ genotypes randomized to neuroblastoma immunotherapy or FL maintenance immunotherapy had better
outcome versus those randomized to no immunotherapy
for neuroblastoma or non-maintenance for FL. In
contrast, for those with KIR3DL1+/B-Bw4-I80+, there
was no evidence of a difference in outcome between
immunotherapy vs. no-immunotherapy [40]. These combined results suggest that the correlation between these
KIR/KIR-ligand genotypes and outcome may serve as a
biomarker for identifying those that might benefit from
this type of immunotherapy using tumor-reactive mAb.
Furthermore, these results suggest similar analyses of
KIR/KIR-ligand genotype and immunotherapy should be
pursued for other clinical trials in other diseases that
utilize other tumor-reactive mAbs to see if these findings
we have noted for rituximab in FL and dinutuximab in
neuroblastoma might extend to other cancers treated
with other tumor-reactive mAb [40].
In addition, in this study, amongst patients that received rituximab maintenance, those that are KIR3DL1
+/Bw4+ showed significantly improved TTRF, duration
of response and tumor shrinkage than for those not
KIR3DL1+/Bw4+. Similarly, amongst patients that received rituximab maintenance, those that are Group-1
(KIR2DL2+/C2+ and KIR3DL1+/Bw4+) showed improved TTRF, duration of response and tumor shrinkage
than those that are Group-2 (not KIR2DL2+/C2+ and
KIR3DL1+/Bw4+). These demonstrate an association
(likely via ADCC) of KIR/KIR-ligand genotype on the
outcome of rituximab maintenance therapy.
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Several studies have found associations of patient
response to treatment with KIR2DL2 status, with or
without its ligand, HLA-C1 [41–43]. In a study of neuroblastoma patients mentioned previously, we found that
patients that had both KIR2DL2+/C1+ [KIR2DL2+ and
HLA-C1+ (C1/C1 or C1/C2)] and KIR3DL1+/Bw4+ (i.e.
Group 1) had improved clinical outcome if treated with
monoclonal antibody-based immunotherapy compared
to no-immunotherapy [38].
In addition to assessing the influence of HLA-Bw4 on
clinical outcome, Du and colleagues found that FL patients that were missing both HLA-C2 and HLA-Bw4
and were treated with either rituximab and galaximib, or
rituximab and epratuzamab, had longer duration of
response than those individuals that possessed both of
those KIR-ligands [12]. That analysis focused on the
subsets of patients with both HLA-C2 and HLA-Bw4 or
missing both HLA-C2 or HLA-Bw4, but excluded the
subsets with only one or the other of these combinations. In our analysis here of FL patients treated with
maintenance or non-maintenance rituximab, we included all patients in each comparative analysis, and also
considered the inhibitory KIR gene status, when evaluating KIR2DL1, KIR2DL2 or KIR2DL3, with their respective ligands with KIR3DL1 and its HLA-Bw4 ligand.
With respect to HLA-C status and HLA-Bw4 status,
following assessment of all possible KIR2DL1, KIR2DL2
or KIR2DL3, with their respective ligands (HLA-C1 or
HLA-C2) and with KIR3DL1 and its ligand (HLA-Bw4),
our analysis suggests patients that are both KIR2DL2
+/C1+ and KIR3DL1+/Bw4+ (Group 1) had improved
clinical outcome if treated with rituximab maintenance
compared with the non-maintenance treatment schedule. However, as the subpopulations of patients with
varying KIRs and KIR-ligands studied in each report are
different, and the exact therapy we used (rituximab
maintenance) was different than that used by Du et al.
(rituximab and galaximib, or rituximab and epratuzamab), we cannot actually determine whether our results
are discordant from those of Du et al.
Kahl and colleagues used TTRF as their primary endpoint in the primary clinical report of this trial, as it may
provide more value to understanding of the clinical
benefit of rituximab than using duration of response as
an endpoint [6, 8]. Rituximab has limited side effects
compared with cytotoxic chemotherapeutic agents,
which have more adverse side effects [8], and the TTRF
can reflect when progressive or unresponsive disease
requires initiation of cytotoxic chemotherapy. If a maintenance schedule can, for some patients, delay the need
for cytotoxic therapy, this could provide clinical benefit
[44, 45]. In our analyses of the TTRF parameter shown
in this report, we considered only those failure events
that were considered to be biologically relevant. In the
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primary study report, Kahl et al. noted no difference in
time to rituximab failure between the maintenance and
non-maintenance schedules when all patients were evaluated independent of genotype [6]. However, in this report, by assessing different genotype groupings of KIRs/
KIR-ligands, we were able to identify a set of patients
(Group 1: KIR2DL2+/C1+/KIR3DL1+/Bw4+), reflecting
28% of this patient population, that may have prolonged
TTRF if treated with maintenance rituximab as compared to non-maintenance. This finding provides some
evidence that rituximab maintenance may still provide a
clinically meaningful benefit for a subgroup of patients
based on their KIR/KIR-ligand genotypes.
Most NK cells express an array of both inhibitory and
activating receptors; NK cell activation reflects the
balance of both activating and inhibitory signals. The
clinical data and associations presented in this report
suggest that there are in vivo interactions that were
simultaneously influenced by inhibitory KIRs and their
ligands, and activating signaling through stimulation
with mAb (rituximab), which appeared to also reflect
influences on NK cell licensing [35]. While this report
focuses on the associations of inhibitory-KIR/KIR-ligand
genotype with clinical outcome for this clinical trial,
patients from this same clinical trial were also evaluated
for other KIR-related genotype associations. We also
evaluated associations of KIR haplotype (A or B) with
clinical outcome, but found no associations with clinical
outcome (data not shown) [24]. In addition, for this
same ECOG-ACRIN study, Kenkre et al. assessed genotypes for high and low affinity allelic variants of the
activating Fc gamma receptors (FCGR), FCGR3A and
FCGR2A, and found no associations with clinical outcome [46].

Conclusions
In summary, the associations of outcome and KIR/KIRligand genotypes presented here demonstrate some role
for KIR recognition of KIR-ligands in the in vivo response to rituximab therapy in at least some patients
with FL. In particular, the 28% of patients in this trial
that have the Group 1 genotype had an association of
clinical outcome benefit with administration of the rituximab maintenance treatment schedule. Whether the
statistically significant benefit in outcome for this subset
shown here merits prospective testing (via genotyping of
all patients to identify this group for further analyses of
maintenance treatment) requires consideration of medical as well as cost-related issues. Furthermore, as the
associations observed here are based on relatively small
numbers of patients in the individual comparative
groups, separate validation may be helpful before considering whether this KIR/KIR-ligand genotyping should
be used prospectively for treatment assignment
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decisions. In addition, based on the findings described
here, as well as our similar findings using other monoclonal antibodies [30], it may be of interest to study the
impact of KIR and KIR-ligands with the newer
anti-CD20 antibodies, obinutuzumab and ofatumumab,
which have shown efficacy in treatment of indolent
non-Hodgkin lymphomas [47, 48]. Finally, the associations reported here likely reflect the regulation of NK
cells mediating in vivo ADCC as a result of the rituximab therapy, consistent with other preclinical and clinical data. Thus these data further support the roles that
KIR and KIR-ligands play, for at least some patients, in
the setting of certain types of cancer immunotherapy.
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